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Angiotensin I-converting enzyme and angiotensinogen gene interaction
and prediction of essential hypertension. To prove whether the interac-
tion between insertion/deletion (I/D) angiotensin I converting enzyme
(ACE) and M235T angiotensinogen (AGT) gene polymorphic alleles
could contribute to causing essential hypertension, we examined subjects
from the Czech Republic (365 Caucasians total; 202 normotensives and
163 hypertensives). Subjects were genotyped for insertion/deletion poly-
morphism of ACE (I/D ACE, intron 16) and for M235T polymorphism of
angiotensinogen gene (AGT, exon 2) by means of the polymerase chain
reaction (PCR) method. The case-control approach was used. Fisher’s
exact test followed by Holmes’s test to overcome the problem of multiple
comparisons were used for the statistical analysis of data. No association
of single gene allelic variants with essential hypertension was found in our
population. Having compared only double homozygote combinations, the
association of the DDMM genotype with essential hypertension was
proven (P 5 0.0081). To the contrary, IITT (P 5 0.0086) was found more
frequently in normotensive subjects. We conclude that the interaction of
the I/D ACE and M235T AGT polymorphic alleles can contribute to
essential hypertension, despite the absence of single gene associations with
the condition.
The aim of this study was to prove whether the interaction
between insertion/deletion (I/D) angiotensin I converting enzyme
(ACE) and M235T angiotensinogen (AGT) gene polymorphic
alleles could contribute to the occurrence of essential hyperten-
sion.
Blood pressure is a quantitative, multifactorial trait of hetero-
geneous origin, in which the definition of abnormality is arbitrary.
It reflects a complex interaction between genetic and environmen-
tal factors, with genetic susceptibility accounting for much of the
variation in blood pressure within populations and environmental
factors determining the variation between populations [1]. The
genetic background not only determines the actual blood pressure
response to environmental conditions, but also the susceptibily of
target tissues (heart, blood vessels and kidney) to stressors such as
the high blood pressure [2]. Hypertension is often a cause of
human cardiovascular morbidity and mortality because it consti-
tutes a major risk for cardiac and cerebral infarction, cerebral
hemorrhage, and cardiac and renal failure.
The renin-angiotensin system (RAS) is a hormonal system in
the classical sense, meaning that it is a circulating hormone acting
on a target organ. The system apparently functions independently
at the tissue level in a paracrine and autocrine manner. Subtle
derangements in this system that may arise in childhood, most
likely from a genetic predisposition, almost certainly form the
basis for hypertensive conditions [3]. Laragh proposed that the
main pathophysiological problem of essential hypertension is in
kidney with a heterogeneous population of nephrons, some
hyperfiltering and other ischemic [4]. The heterogeneity arises in
patients with kidney having an abnormal hemodynamic response
to angiotensin II (AT II).
Angiotensinogen as well as angiotensin I converting enzyme
variations are supposed to have a role in predisposing the
individuals to essential hypertension. The functional influences of
the variability at both genes have not been fully established thus
far. I/D angiotensin converting enzyme (ACE) polymorphism has
been associated with the level af ACE in serum [5]. An indepen-
dent effect of blood group ABO on the serum level of ACE was
recently described [6]. An enhanced pressor response to angio-
tensin I in normotensive men with a DD genotype for I/D ACE
polymorphism was shown, probably as a consequence of the
generation of increased levels of angiotensin II [7]. The DD
genotype was associated with a significantly greater common
carotid artery wall thickness (P 5 0.003) [8], without a simulta-
neous association of the I/D ACE polymorphism with blood
pressure values according to monitored 24-hour ambulatory blood
pressure values.
The M235T AGT polymorphism codetermines the plasma
levels of angiotensinogen, with increasing levels from MM to TT
genotypes observed both in hypertensive [9, 10] and healthy
populations [11]. T235 allele was found to be associated with the
extent of coronary lesions, which were detected in angiograms in
patients with coronary artery disease with a low-risk status in a
multigenic study of genetic polymorphisms [12]. Recently, a new
polymorphism [G(26)A] in the angiotensinogen gene promotor
was found. The polymorphism was associated with essential
hypertension [13] and is supposed to affect the basal transcription
rate of the gene according to tests of promoter activity and to
DNA binding studies in vitro. T variant of M235T AGT polymor-
phism is in tight linkage disequilibrium with the mutation in the
angiotensinogen promotor G(26)A, which leads to elevated
expression in vitro. Expression of the T235 allele is significantly
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higher in decidual spiral arteries of heterozygous women (MT),
suggesting that elevated expression of T235 in decidual spiral
arteries may cause vascular changes leading to preeclampsia [14].
METHODS
The case-control method was used to study two genetic poly-
morphisms of the RAS system in our normotensive and hyper-
tensive populations. A sample of healthy population (306 Cauca-
sians, Czech nationality, industrial city of Brno with 400,000
inhabitants) was examined by the 24-hour blood pressure moni-
toring (SpaceLab 90 207). The sample included the entire cohorts
(men 40 to 45 years, women 45 to 50 years) of one general
practitioner, in which essential hypertension had not been diag-
nosed thus far. Two hundred and two subjects were diagnosed as
normotensives (controls defined as having , 20% BP values
above 140/90 mm Hg during the daytime and/or , 20% BP values
above 120/80 mm Hg during the night). Fifty-one subjects were
newly diagnosed as essential hypertensives according to the
criteria of Zachariah et al for 24-hour BP monitoring (.40%
values over 140/90 mm Hg from 6:00 to 22:00 and/or . 40% over
120/80 mm Hg from 22:00 to 6:00 the next day) [15]. The other 53
subjects had . 20% values above 140/90 mm Hg during the
daytime and/or . 20% values above 120/80 mm Hg during the
night, and these subjects were excluded from the next statistical
analysis. Cases consisted of 112 outpatients of the internal med-
icine clinic who had been diagnosed with and treated for essential
hypertension, and of the 52 subjects newly diagnosed with essen-
tial hypertension in which nonpharmacological and/or pharmaco-
logical interventions were initiated. The patients with secondary
hypertension and/or diabetes mellitus as defined according to
WHO recommendations were excluded.
The study was approved by the Committee for the Ethics of
Medical Experiments on Human Subjects, Medical Faculty,
Masaryk University, Brno (No. 64/93, 1993). Informed consent of
the examined subjects was obtained.
Twenty-four-hour blood pressure monitoring
Each record consisted of 48 to 53 readings of the systolic and
diastolic pressures. The daytime frequency of the measurements
was programmed on a three-measurements-per-hour basis from
6:00 to 22:00 hours; night time measurements were performed on
a one-measurement-per-hour basis from 22:00 until 6:00 hours
the next day.
Genotype identification
The genomic DNA was isolated from peripheral blood leuko-
cytes by a standard method using proteinase K digestion of cells
according to Sambrook et al [16].
The analysis of the insertion/deletion polymorphism in the
angiotensin I converting enzyme gene (I/D ACE) was performed
according to Rigat et al [17] with a subsequent verification of the
DD genotype by the method of Shannugam, Sell and Saha [18].
Using gel electrophoresis, the PCR products were distinguished as
a 190 bp fragment in the absence and a 490 bp fragment in the
presence of the insertion (genotypes described as II-490 bps,
ID-4901190 bps, DD-190 bps). Polymorphism M2353T in the
angiotensinogen gene (M235T AGT) was detected according to
Russ et al [19] (mismatch PCR; restriction analysis with Asp I;
length of bands 165, 141 at 24 bps on gel electrophoresis with
ethidium bromide; genotypes described as MM-165 bps, MT-
1651141 bps, and TT-141 bps).
Statistical analyses
A multivariate analysis of variance was used to calculate the
difference in body mass index (BMI) and sex between the two
groups.
Coincidences of double genotypes were calculated from prob-
abilities of occurrence of possible haploid combinations of the two
gene alleles assuming random combinability of haplotypes (the
genes are located at different chromosomes).
Probability of the more general Hardy-Weinberg equilibrium
(comparisons of the observed and calculated coincidences) for the
two genes as well as the difference in double genotype coincidence
in the case-control study were calculated by the chi2 test.
Comparisons of the allelic variant frequencies as well as
comparisons of double homozygotes to the other double homozy-
gotes in the case-control study were performed by Fisher’s exact
test.
The Holm’s test for multiple comparisons was used where
appropriate. The software program Statistic, version 3.0 (Statsoft
Inc., Tulsa, OK, USA) was used in all of the calculations.
RESULTS
Using the multivariate analysis of variance, a highly significant
difference in BMI between cases and controls was found (P 5
0.000003). This difference was not dependent on gender.
There were no significant differences in allelic frequencies of
the examined genes between the two groups when they were
calculated separately (Table 1).
Both controls (P 5 0.729778) and cases (P 5 0.062687) were
found to be in equilibrium in double genotype coincidence (Table
2). A bordeline difference in double genotype coincidence was
found (P 5 0.054) in the case-control comparison.
Table 1. I/D ACE and M235T AGT allele frequencies in the case-control study
BMI kg/m2 Age years
I/D ACE M235T AGT
I D M T
Controls (N 5 202) 25.4 6 3.3 46 6 3 0.41 0.59 0.54 0.46
M/W 5 86/116
Cases (N 5 163) 27.5 6 4.3 50 6 9 0.38 0.62 0.60 0.40
M/W 5 95/68
Probability of
difference
0.000003 NS 0.223182 0.086607
Abbreviations are: M/W, males/ females; BMI, body mass index; I/D ACE, insertion/deletion polymorphism of angiotensin converting enzyme gene;
AGT, angiotensinogen gene. I, D, M and T are alleles.
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The double homozygote coincidence was different when the
cases and controls were compared. Statistically significant differ-
ences were found in two of the four possible homozygous combi-
nations (Table 3): genotype DDMM was more frequent in the
cases (P 5 0.008086), while IITT genotype was more frequent in
the controls (P 5 0.008619). After recalculation of probabilities by
the Holm’s test, the probability remained under 0.05.
DISCUSSION
Isolated I/D ACE gene polymorphism in essential hypertension
has been studied often [20–22], as has isolated M235T AGT
polymorphism [23–27], with researchers using varied study de-
signs and finding disparate, often negative, results.
Having compared allelic frequencies of M235T AGT polymor-
phism in the studies, our results show a nonsignificant increase in
the M allelic frequency, especially in the controls. Our control
group included 202 normotensive subjects confirmed by 24-hour
blood pressure monitoring. Surprisingly, only a few genetic studies
have used 24-hour monitoring to determine blood pressure,
although the method is more accurate and gives more precise
information than office blood pressure. None of the studies
[28–30] evaluated both polymorphisms. Another important factor
improving the differences in allelic frequency in Caucasian pop-
ulations is a high homogeneity of Czech population historically.
The known shift in the incidence of ABO blood groups in
European Caucasians could also contribute to the differences.
If the two polymorphisms mentioned above contribute (though
slightly) to a genetic background affecting blood pressure and
their contribution can be considered to be additive or multiplica-
tive, then the incidence of double homozygotes compared to the
other double homozygotes could be expected to be shifted
between normotensives and hypertensives. The genotype MMDD
supposedly can be characterized by combination of a high activity
of ACE and a low level of angiotensinogen. The variant was
proven to be associated with hypertension. To the contrary,
genotype IITT, phenotypically characterized as combination of
the lowest activity of ACE and the highest level of angiotensino-
gen, was found to be associated with normal blood pressure.
Another variant, IIMM (the lowest activity of ACE and the lowest
level of angiotensinogen), did not differ between normotensives
and hypertensives in occurrence. Getopyte DDTT (the highest
activity of ACE with the highest level of angiotensinogen) seems
to slightly diminish the risk of hypertension.
Further candidate gene analysis can be expected to elucidate
the genetic background of essential hypertension in future.
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